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Keratitis-ichthyosis-deafness (KID) syndrome is a con-
genital disorder, which is associated with mutations in 
the GJB2 gene encoding connexin 26 or in the closely 
related connexin 30 gene, GJB6. To date, approximately 
100 cases have been described, mainly sporadic, but auto-
somal dominant inheritance has been reported in a small 
number of families. The syndrome is characterized by 
profound sensorineural hearing loss accompanied by vas-
cularizing keratitis and erythrokeratoderma-like skin le-
sions. Palmoplantar hyperkeratosis, alopecia, dystrophic 
nails, and increased susceptibility to bacterial, viral and 
fungal infections and squamous cell carcinoma are other 
common features of this syndrome (1, 2). Treatment of 
patients with KID syndrome is difficult and often disap-
pointing. Systemic retinoids, acitretin or isotretinoin have 
been used in patients with KID syndrome with variable 
success (3–6). We report here a case of KID syndrome 
where dissecting cellulitis of the scalp was treated suc-
cessfully with alitretinoin.
CASE REPORT
A 15-year-old boy, born of non-consanguineous healthy parents, 
presented to our department in 2002 with a history of red and 
dry skin since birth, sensorineural deafness, red-brown hyper-
keratotic plaques on his face and extremities, and sparse hair. 
Paronychia with nail dystrophy affected most of his fingers and 
all his toes. In 2003 he was the first Danish patient in whom 
KID syndrome was verified by mutation analysis, showing a 
heterozygous missense mutation D50N (148G >A) in GJB2 (6). 
The patient had a history of several unsuccessful treatments. 
Topical treatments with calcipotriol, corticosteroids and tar had 
been used with no effect. Pulsed dye laser had also been tried 
with no effect. Etretinate (Tigason, Betapharma, Shanghai) 10 
mg per week was introduced when he was only one year of age. 
He continued this treatment for 4 months with no effect. From 
the age of 5 to 7 years he was treated with acitretin (Neotiga-
son, Actavis, UK) 10 mg daily, but had to stop the treatment 
because of erosive skin lesions in his auditory canals. In the 
following years, his skin lesions and nail surroundings had 
often been infected with dermatophytes, Candida and pyogenic 
bacteria, thus he needed frequent treatments with topical and 
systemic antibiotics and antimycotic drugs. At the age of 17 
years, treatment with acitretin was resumed as he showed a 
follicular occlusion triad, with dissecting cellulitis of the scalp, 
cystic acne and hidradenitis in his axillary regions and groins. 
Acitretin 20 mg daily for 2 months did not alter his condition 
and a higher dose was not possible because of side-effects. As 
the treatment did not improve his condition, isotretinoin (Roac-
cutan, Roche, Switzerland) 20–30 mg daily in combination 
with prednisolone 25 mg daily were initiated and combined 
with dicloxacillin. In this period he was regularly examined by 
an ophthalmologist, to ensure that systemic retinoids did not 
provoke a keratitis or other ophthalmic side-effects. He had 
continuous painful dissecting cellulitis of his scalp (Fig. 1A) 
and was regularly receiving wound care in the outpatient clinic. 
A plastic surgeon was consulted, who considered transplanta-
tion of skin on his whole scalp. Photodynamic therapy was also 
tried with no effect. However, some improvement was seen after 
systemic treatment with clindamycin (Dalacin) and rifampicin 
(Rimactan) given for 3 months, followed by the antimycotic 
drug itraconazole (Sporanox). In 2009 the patient developed 
an ulcer on his left leg. The sudden onset of the ulcer and its 
slow healing resulted in several biopsies being taken from the 
ulcer in order to exclude malignant or premalignant changes. 
The hyperkeratotic plaques on his leg hampered healing of 
the ulcer, thus he resumed treatment with acitretin. Within 
2 months acitretin was discontinued, because of aggravation 
in his skin condition. It was clear that the patient´s condition 
would not improve with acitretin, thus alitretinoin (Toctino, 
Basilea, Switzerland) was considered. The ulcer continued for 
almost one year. Once the ulcer was healed, we decided to 
initiate alitretinoin off-label at an initial dose of 10 mg daily 
for 2 months, followed by a maintenance dose of 20 mg daily. 
Blood tests, including thyroxin (T4) and thyroid-stimulating 
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Fig. 1. Clinical images showing dissecting cellulitis of the scalp (A) before and (B) after treatment with alitretinoin 10–20 mg/day for 5 months.
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hormone (TSH) levels, were taken before and during the therapy 
at regular intervals, with normal results. A significant impro-
vement in all of his skin lesions was detectable after 5 months 
of therapy (Fig. 1B). The red-brown hyperkeratotic plaques on 
his face and extremities, dissecting cellulitis of the scalp and 
hidrosadenitis were significantly decreased, and a longstanding 
tendency to fissuring of his hands and feet stopped. During the 
course of treatment there were no detectable adverse effects, 
except a slight tendency to erosive skin lesions in his auditory 
canals. As the dose was reduced to 10 mg/day these symptoms 
subsided and treatment could be continued. The patient is still 
receiving treatment with alitretinoin, and currently he is less 
troubled by his skin symptoms. Only moisturizing ointment 
(Locobase), soothing baths with wheat-bran, and occasional 
potassium permanganate baths, are administered.
DISCUSSION
We describe here a case of KID syndrome showing a 
significant treatment response to low-dose alitretinoin. 
Patients with KID are often resistant to treatments, 
thus a variety of treatments may be tried, with variable 
and often limited success. Systemic retinoids interfere 
with the terminal differentiation of keratinocytes, and 
have been shown to be effective in many disorders of 
keratinization. However, the potential side-effects of 
systemic retinoids are of concern (4). Several case re-
ports on the use of acitretin or isotretinoin, with variable 
results, have been published (3–6).
Retinoids regulate a variety of metabolic processes 
that promote cell growth and function, such as cellular 
differentiation, proliferation and apoptosis. Retinoids 
exert their effects on target cells by activating nuclear 
retinoid receptors. Alitretinoin is capable of binding to 
all known retinoic acid receptors (RARs) and retinoid X 
receptors (RXRs), in contrast to acitretin, which activa-
tes but does not bind to RARs, and isotretinoin, which 
shows low affinity for RARs. Alitretinoin is therefore 
expected to have more diverse effects in a different 
spectrum of diseases (7).
In most European countries alitretinoin is hitherto 
only legislated for chronic hand eczema (8). The effect 
of ali tretinoin in KID syndrome has been published 
previously in only one case report (5). The patient 
in this case received alitretinoin 30 mg per day as a 
maintenance dose for 5 months, and during the course 
of treatment there were no detectable adverse effects. 
After 5 months of therapy the infiltrated erythema on 
the face had decreased, and the hyperkeratotic plaques 
had almost completely disappeared (5). In our patient 
the hyperkeratotic skin lesions were treated with topical 
moisturizers, keratolytic agents, potassium permanga-
nate baths, and alitretinoin. Alitretinoin reduced the 
severity of the hyperkeratotic plaques during the first 
months of treatment, and had a positive effect on the 
dissecting cellulitis, and thus improved our patient’s 
quality of life. Our patient showed a significant impro-
vement in his scalp and skin symptoms, which indicated 
that long-term continuous therapy with alitretinoin may 
be a possibility in patients with KID with severe dis-
secting cellulitis. 
The prognosis of KID syndrome depends on early 
diagnosis of infections and skin cancers. These patients 
need lifelong follow-up for early diagnosis of malig-
nant tumours, especially squamous cell carcinomas of 
the hyperkeratotic skin and mucosa (4, 6). Systemic 
retinoids reduce the hyperkeratosis and may reduce the 
incidence of skin cancer. We conclude that treatment 
with systemic alitretinoin may be an option for KID 
syndrome in cases complicated with follicular occlusion 
and dissecting cellulitis. Continuous monitoring for ad-
verse effects remains essential, and more research into 
alitretinoin therapy is needed in order to determine the 
most effective dosage and the long-term safety of this 
medication in disorders of keratinization (9).
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